Cargando…

Randomised controlled trial of a secondary prevention program for myocardial infarction patients ('ProActive Heart'): study protocol. Secondary prevention program for myocardial infarction patients

BACKGROUND: Coronary heart disease (CHD) is a significant cause of health and economic burden. Secondary prevention programs play a pivotal role in the treatment and management of those affected by CHD although participation rates are poor due to patient, provider, health system and societal-level b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hawkes, Anna L, Atherton, John, Taylor, C Barr, Scuffham, Paul, Eadie, Kathy, Miller, Nancy Houston, Oldenburg, Brian
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689849/ https://www.ncbi.nlm.nih.gov/pubmed/19426524 http://dx.doi.org/10.1186/1471-2261-9-16

Ejemplares similares

Cost-effectiveness of a coronary heart disease secondary prevention program in patients with myocardial infarction: results from a randomised controlled trial (ProActive Heart)
por: Turkstra, Erika, et al.
Publicado: (2013)

Secondary Prevention of Myocardial Infarction in People Living With HIV Infection
por: Erqou, Sebhat, et al.
Publicado: (2020)

Secondary Prevention of Myocardial Infarction With Nonpharmacologic Strategies in a Medicaid Cohort
por: Oberg, Erica B., et al.
Publicado: (2009)

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction
por: Kehinde, Obamiro, et al.
Publicado: (2016)

Going beyond the mean: economic benefits of myocardial infarction secondary prevention
por: von Wyl, Viktor, et al.
Publicado: (2020)

Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus
por: Jørgensen, Casper H, et al.
Publicado: (2014)

Association of secondary prevention medication use after myocardial infarction with mortality in hemodialysis patients
por: Lin, Ting-Yun, et al.
Publicado: (2022)

Management and outcome across the spectrum of high‐risk patients with myocardial infarction according to the thrmobolysis in myocardial infarction (TIMI) risk‐score for secondary prevention
por: Grinberg, Tzlil, et al.
Publicado: (2021)

Cumulative Adherence to Secondary Prevention Guidelines and Mortality After Acute Myocardial Infarction
por: Solomon, Matthew D., et al.
Publicado: (2020)

Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decade
por: Atar, Dan, et al.
Publicado: (2014)

Long-term secondary prevention of acute myocardial infarction (SEPAT) – guidelines adherence and outcome
por: Ergatoudes, Constantinos, et al.
Publicado: (2016)

Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction
por: Halvorsen, Sigrun, et al.
Publicado: (2016)

Beta-Blockers for the Secondary Prevention of Myocardial Infarction in People with Dementia: A Systematic Review
por: Lanham, David, et al.
Publicado: (2019)

The influence of treatment modality on illness perception and secondary prevention outcomes among patients with acute myocardial infarction
por: Al-Smadi, Ahmed Mohammad, et al.
Publicado: (2017)

Secondary Prevention Medical Therapy and Outcomes in Patients With Myocardial Infarction With Non-Obstructive Coronary Artery Disease
por: Paolisso, Pasquale, et al.
Publicado: (2020)

Medication-taking for secondary prevention of acute myocardial infarction: a thematic meta-synthesis of patient experiences
por: Piekarz, Hannah, et al.
Publicado: (2022)

Repetitive Myocardial Infarctions Secondary to Delirium Tremens
por: Schwartzberg, David, et al.
Publicado: (2014)

Acute Myocardial Infarction Secondary to Paradoxical Embolism
por: Alenezi, Abdullah R, et al.
Publicado: (2020)

Predictors of physical and mental health-related quality of life outcomes among myocardial infarction patients
por: Hawkes, Anna L, et al.
Publicado: (2013)

Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction
por: Weiss, Thomas W., et al.
Publicado: (2016)

Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting
por: Liang, Zhe, et al.
Publicado: (2021)

Atherothrombotic risk stratification after acute myocardial infarction: The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non‐ST Elevation Myocardial Infarction registries
por: Puymirat, Etienne, et al.
Publicado: (2018)

Effects of Bisoprolol Are Comparable with Carvedilol in Secondary Prevention of Acute Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention
por: Jun, Seung Jin, et al.
Publicado: (2018)

Risk factors and prognostic role of an electrical storm in patients after myocardial infarction with an implanted ICD for secondary prevention
por: Kwaśniewski, Wojciech, et al.
Publicado: (2016)

Impact of combination therapy with statin and ezetimibe on secondary prevention for post-acute myocardial infarction patients in the statin era
por: Ebisawa, Soichiro, et al.
Publicado: (2015)

Trends in Myocardial Infarction Secondary Prevention: The National Health and Nutrition Examination Surveys (NHANES), 1999–2012
por: Shah, Nilay S., et al.
Publicado: (2015)

Association of Socioeconomic Status With Risk Factor Target Achievements and Use of Secondary Prevention After Myocardial Infarction
por: Ohm, Joel, et al.
Publicado: (2021)

Secondary prevention strategies after an acute ST-segment elevation myocardial infarction in the AMI code era: beyond myocardial mechanical reperfusion
por: Ribas, Núria, et al.
Publicado: (2017)

Acute myocardial infarction secondary to mucormycosis after lung transplantation
por: Naik, Chetan A., et al.
Publicado: (2020)

ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION SECONDARY TO COVID-19
por: DOUEDI, STEVEN, et al.
Publicado: (2021)

Risk of Parkinson Disease and Secondary Parkinsonism in Myocardial Infarction Survivors
por: Sundbøll, Jens, et al.
Publicado: (2022)

Perioperative myocardial infarction: diagnostic clues and prevention
por: Nichols, Larry
Publicado: (2018)

Prevention of Ventricular Arrhythmias after Myocardial Infarction
por: Kidner, P. H.
Publicado: (1977)

SYSTEMIC THROMBOEMBOLISM SECONDARY TO ACUTE MYOCARDIAL INFARCTION IN A PATIENT WITH CORONAVIRUS DISEASE
por: Yamada, Takeshi, et al.
Publicado: (2022)

Qi-Shen-Yi-Qi Dripping Pills for the Secondary Prevention of Myocardial Infarction: A Randomised Clinical Trial
por: Shang, Hongcai, et al.
Publicado: (2013)

Self‐Controlled Case‐Series Study to Verify the Effect of Adherence to Beta‐Blockers in Secondary Prevention of Myocardial Infarction
por: Di Bartolomeo, Stefano, et al.
Publicado: (2015)

Trends and variations in the prescribing of secondary preventative cardiovascular therapies for non-ST elevation myocardial infarction (NSTEMI) in Malaysia
por: Venkatason, Padmaa, et al.
Publicado: (2018)

Association of Diabetes Mellitus Status and Glycemic Control With Secondary Prevention Medication Adherence After Acute Myocardial Infarction
por: Adamek, Kylie E., et al.
Publicado: (2019)

Development of a Yoga-Based Cardiac Rehabilitation (Yoga-CaRe) Programme for Secondary Prevention of Myocardial Infarction
por: Chattopadhyay, Kaushik, et al.
Publicado: (2019)

Determinants of suboptimal long-term secondary prevention of acute myocardial infarction: the structural interview method and physical examinations
por: Sakalaki, Maria, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_397outdvruldurpoia64s4kvav